Cargando…

Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial

BACKGROUND: Flexibility of vaccination schedule and lower antigen content can facilitate pandemic vaccine coverage. We assessed the immune response and safety of AS03-adjuvanted A/California/7/2009 H1N1 pandemic vaccine containing half of the registered adult haemagglutinin (HA) antigen content, adm...

Descripción completa

Detalles Bibliográficos
Autores principales: Duval, Xavier, Caplanusi, Adrian, Laurichesse, Henri, Deplanque, Dominique, Loulergue, Pierre, Vaman, Tejaswini, Launay, Odile, Gillard, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522029/
https://www.ncbi.nlm.nih.gov/pubmed/22824474
http://dx.doi.org/10.1186/1471-2334-12-162
_version_ 1782253030567051264
author Duval, Xavier
Caplanusi, Adrian
Laurichesse, Henri
Deplanque, Dominique
Loulergue, Pierre
Vaman, Tejaswini
Launay, Odile
Gillard, Paul
author_facet Duval, Xavier
Caplanusi, Adrian
Laurichesse, Henri
Deplanque, Dominique
Loulergue, Pierre
Vaman, Tejaswini
Launay, Odile
Gillard, Paul
author_sort Duval, Xavier
collection PubMed
description BACKGROUND: Flexibility of vaccination schedule and lower antigen content can facilitate pandemic vaccine coverage. We assessed the immune response and safety of AS03-adjuvanted A/California/7/2009 H1N1 pandemic vaccine containing half of the registered adult haemagglutinin (HA) antigen content, administered as a two-dose schedule at intervals of 21 days or 6 months in both young and elderly adults. METHODS: In this open-label randomized trial, healthy adults aged 18–60 years (N = 163) and >60 years (N = 143) received AS03(A)-adjuvanted A/California/7/2009 H1N1 vaccine containing 1.9 μg HA on Day 0. A second dose was given on Day 21 (n = 177) or Day 182 (n = 106). Haemagglutination-inhibition (HI) antibody responses were analyzed on Days 0, 21, 42, 182, 364 and additionally on Day 203 for subjects vaccinated on Day 182. Solicited and unsolicited adverse events were recorded. RESULTS: The HI antibody response in both age strata 21 days after the first dose met and exceeded all regulatory acceptance criteria although the results suggested a lower response in the older age stratum (geometric mean titres [GMTs] for HI antibodies of 420.5 for subjects aged 18–60 years and 174.4 for those >60 years). A second dose of AS03(A) adjuvanted A/H1N1/2009 vaccine induced a further increase in antibody titres and the response was similar whether the second dose was administered at 21 days (GMTs of 771.8 for 18–60 years and 400.9 for >60 years) or 6 months (GMTs of 708.3 for 18–60 years and 512.1 for >60 years) following the first dose. Seroprotection rates remained high at 6 months after one dose or two doses while at 12 months rates tended to be higher for the 6 month interval schedule (93.3% for 18–60 years and 80.4% for >60 years) than the 21 day schedule (82.3% for 18–60 years and 50.0% for >60 years). Reactogenicity/safety profiles were similar for both schedules, there was no evidence of an increase in reactogenicity following the second dose. CONCLUSIONS: The results indicate that flexibility in the dosing interval for AS03(A) adjuvanted vaccine may be possible. Such flexibility could help to reduce the logistic stress on delivery of pandemic vaccination programmes. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00975884
format Online
Article
Text
id pubmed-3522029
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35220292012-12-14 Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial Duval, Xavier Caplanusi, Adrian Laurichesse, Henri Deplanque, Dominique Loulergue, Pierre Vaman, Tejaswini Launay, Odile Gillard, Paul BMC Infect Dis Research Article BACKGROUND: Flexibility of vaccination schedule and lower antigen content can facilitate pandemic vaccine coverage. We assessed the immune response and safety of AS03-adjuvanted A/California/7/2009 H1N1 pandemic vaccine containing half of the registered adult haemagglutinin (HA) antigen content, administered as a two-dose schedule at intervals of 21 days or 6 months in both young and elderly adults. METHODS: In this open-label randomized trial, healthy adults aged 18–60 years (N = 163) and >60 years (N = 143) received AS03(A)-adjuvanted A/California/7/2009 H1N1 vaccine containing 1.9 μg HA on Day 0. A second dose was given on Day 21 (n = 177) or Day 182 (n = 106). Haemagglutination-inhibition (HI) antibody responses were analyzed on Days 0, 21, 42, 182, 364 and additionally on Day 203 for subjects vaccinated on Day 182. Solicited and unsolicited adverse events were recorded. RESULTS: The HI antibody response in both age strata 21 days after the first dose met and exceeded all regulatory acceptance criteria although the results suggested a lower response in the older age stratum (geometric mean titres [GMTs] for HI antibodies of 420.5 for subjects aged 18–60 years and 174.4 for those >60 years). A second dose of AS03(A) adjuvanted A/H1N1/2009 vaccine induced a further increase in antibody titres and the response was similar whether the second dose was administered at 21 days (GMTs of 771.8 for 18–60 years and 400.9 for >60 years) or 6 months (GMTs of 708.3 for 18–60 years and 512.1 for >60 years) following the first dose. Seroprotection rates remained high at 6 months after one dose or two doses while at 12 months rates tended to be higher for the 6 month interval schedule (93.3% for 18–60 years and 80.4% for >60 years) than the 21 day schedule (82.3% for 18–60 years and 50.0% for >60 years). Reactogenicity/safety profiles were similar for both schedules, there was no evidence of an increase in reactogenicity following the second dose. CONCLUSIONS: The results indicate that flexibility in the dosing interval for AS03(A) adjuvanted vaccine may be possible. Such flexibility could help to reduce the logistic stress on delivery of pandemic vaccination programmes. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00975884 BioMed Central 2012-07-23 /pmc/articles/PMC3522029/ /pubmed/22824474 http://dx.doi.org/10.1186/1471-2334-12-162 Text en Copyright ©2012 Duval et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Duval, Xavier
Caplanusi, Adrian
Laurichesse, Henri
Deplanque, Dominique
Loulergue, Pierre
Vaman, Tejaswini
Launay, Odile
Gillard, Paul
Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial
title Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial
title_full Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial
title_fullStr Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial
title_full_unstemmed Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial
title_short Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial
title_sort flexibility of interval between vaccinations with as03(a)-adjuvanted influenza a (h1n1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522029/
https://www.ncbi.nlm.nih.gov/pubmed/22824474
http://dx.doi.org/10.1186/1471-2334-12-162
work_keys_str_mv AT duvalxavier flexibilityofintervalbetweenvaccinationswithas03aadjuvantedinfluenzaah1n12009vaccineinadultsaged1860and60yearsarandomizedtrial
AT caplanusiadrian flexibilityofintervalbetweenvaccinationswithas03aadjuvantedinfluenzaah1n12009vaccineinadultsaged1860and60yearsarandomizedtrial
AT laurichessehenri flexibilityofintervalbetweenvaccinationswithas03aadjuvantedinfluenzaah1n12009vaccineinadultsaged1860and60yearsarandomizedtrial
AT deplanquedominique flexibilityofintervalbetweenvaccinationswithas03aadjuvantedinfluenzaah1n12009vaccineinadultsaged1860and60yearsarandomizedtrial
AT loulerguepierre flexibilityofintervalbetweenvaccinationswithas03aadjuvantedinfluenzaah1n12009vaccineinadultsaged1860and60yearsarandomizedtrial
AT vamantejaswini flexibilityofintervalbetweenvaccinationswithas03aadjuvantedinfluenzaah1n12009vaccineinadultsaged1860and60yearsarandomizedtrial
AT launayodile flexibilityofintervalbetweenvaccinationswithas03aadjuvantedinfluenzaah1n12009vaccineinadultsaged1860and60yearsarandomizedtrial
AT gillardpaul flexibilityofintervalbetweenvaccinationswithas03aadjuvantedinfluenzaah1n12009vaccineinadultsaged1860and60yearsarandomizedtrial